Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7Z3F1
UPID:
LYCHS_HUMAN
Alternative names:
G-protein coupled receptor PGR22
Alternative UPACC:
Q7Z3F1; B2RCI2; D3DPE2; Q4G0Y6; Q53SJ3; Q53TA8; Q69YG8; Q86SP9; Q8N261; Q8N639; Q8N8K3; Q96MV6
Background:
The Lysosomal cholesterol signaling protein, also known as G-protein coupled receptor PGR22, plays a pivotal role in the mTORC1 signaling pathway. It functions as a cholesterol-binding protein, acting as a sensor to signal cholesterol sufficiency to mTORC1. This process involves the protein binding to cholesterol, which disrupts the interaction between the GATOR1 and KICSTOR complexes, thereby promoting mTORC1 signaling.
Therapeutic significance:
Understanding the role of Lysosomal cholesterol signaling protein could open doors to potential therapeutic strategies.